NCT07281495

Taldefgrobep Alfa in Adults With Overweight and Obesity

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With Open-Label Extension to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Taldefgrobep Alfa in Adults Living With Overweight and Obesity

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Biohaven Therapeutics Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	Taldefgrobep Alfa	Subcutaneous injection administered once each week
DRUG	Placebo	Subcutaneous injection (matching placebo) administered once each week
DRUG	Taldefgrobep Alfa	Subcutaneous injection administered once every 4 weeks
DRUG	Placebo	Subcutaneous injection (matching placebo) administered once every 4 weeks

Timeline

• Start date: 2025-11-24
• Primary completion: 2026-09-01
• Completion: 2026-09-01
• First posted: 2025-12-15
• Last updated: 2026-03-20

Locations

20 sites across 1 country: United States

Regulatory

• FDA-regulated drug study